http://rdf.ncbi.nlm.nih.gov/pubchem/patent/TR-200102581-T2

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ec081c4e9e28039420ff78a88a3dc14d
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-585
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-556
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-585
filingDate 2000-03-03-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d63dfd6e36bb128ee5adc22ca9a76107
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c19cb81ee948a410796a6d1c772fa94d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f2a9026eb33e83176ec2f206be15dff3
publicationDate 2002-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber TR-200102581-T2
titleOfInvention Combination therapy of angiotensin conversion enzyme inhibitor and epoxy-sterodial aldosterone antagonist for the treatment of cardiovascular disease.
abstract Combinations of an ACE inhibitor and an epoxy-steroidal aldosterone receptor antagonist are described for use in the treatment of circulation disorders. Therapies of epoxy-steroidal type aldosterone receptor antagonist compounds, such as eplerenone, in combination with an angiontensin conversion enzyme inhibitor, are of particular interest. side effects are reduced.
priorityDate 1999-03-05-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419502867
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID443872

Total number of triples: 29.